We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
27.50 | 1.59% | 1,761.00 | 1,757.50 | 1,758.00 | 1,767.00 | 1,736.00 | 1,736.00 | 14,302,622 | 16:35:11 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 14.69 | 72.38B |
Date | Subject | Author | Discuss |
---|---|---|---|
26/6/2015 11:36 | Difficult one tompion, good chance of a low either today or Monday, so your timing may be on the money IMV. I have a few stocks on my watch list looking tempting. | essentialinvestor | |
26/6/2015 11:35 | Toss a coin? (sorry, couldn't resist) EDIT - I am holding off for now + waiting for a re-test of Oct/Dec intra-day lows | speedsgh | |
26/6/2015 11:34 | Want to add to my holding but can't decide whether to do this today or wait until Monday. Could jump either way on Monday if Greek situation is resolved one way or another. Any thoughts? | tompion | |
26/6/2015 08:30 | SINGAPORE: Pharmaceutical company GlaxoSmithKline (GSK) is investing a further S$77 million to enhance its antibiotic manufacturing facility in Singapore, it announced on Thursday (Jun 25). This is on top of its initial investment of S$60 million committed in 2012. The facility on Quality Road is the company's only production site for amoxicillin, which is the active compound used in the manufacture of antibiotics that are widely prescribed for the treatment of bacterial infections. The money will be used to construct an additional downstream isolation facility for GSK's enzymatic manufacturing facility. This will increase production by 50 per cent and help GSK meet growing demand for antibiotics in emerging markets. | tradermichael | |
24/6/2015 15:51 | sorry 2015 | pugdog | |
23/6/2015 10:29 | GSK had no option but to sell to someone--as you quote is was a condition of the Novartis agreement. But the two vaccines sold were older ones which tackle the same condition for which they now have newer (superior) vaccines so GSK should not lose out because of these sales. | jadeticl3 | |
23/6/2015 09:09 | Yes, you're correct. GlaxoSmithKline has agreed to sell two meningitis vaccines to Pfizer to satisfy antitrust concerns after its recent acquisition of vaccines business of Novartis. The British drugmaker said on Monday that the total consideration for the sale of its Nimenrix and Mencevax products to Pfizer's Irish unit, including some deferred payments, was 115 million euros ($131 million). GSK agreed to sell the two older vaccines, which are marketed outside the United States and had combined sales last year of 34 million pounds ($54 million), to meet concerns raised by the European Commission and other antitrust regulators. Meningitis vaccines were an issue for competition authorities because GSK acquired two rival products from Novartis, known as Menveo and Bexsero. The sale to Pfizer is expected to be completed before the end of the year. | tradermichael | |
22/6/2015 15:50 | Competition issue? | semper vigilans | |
22/6/2015 15:25 | Interesting that Pfizer has acquired two vaccine products from GSK - just when GSK seemed to be focussing on vaccines business. Some kind of deal here (asset swap?) or eventual merger??? | tradermichael | |
22/6/2015 14:57 | Still waiting with my 1300 buy order. Slowly slowly catchy monkey lol | supermarky | |
22/6/2015 14:56 | There's always a bull and bear case for a company. What happens here when interest rates move up? | supermarky | |
22/6/2015 14:47 | Cheers ch1ck | hanse495 | |
19/6/2015 17:30 | With hindsight, Rodders - Lol !!!!!!!!!!!!!!! Still - this time next year, eh !! | eeza | |
19/6/2015 14:10 | I Should have sold at 1600, you live and learn | hanse495 | |
18/6/2015 14:10 | Getting close to a 20% drop here - bear territory. I guess the dividend will sustain it much below here, though if/when Greece blows up it will hardly improve sentiment. | dr biotech | |
16/6/2015 17:54 | even if nothing to the bid rumour it should bounce off support as already said and this will no doubt help, so back in here today, also not too long until the next xd, and even if divi frozen for a while that's fine at a 5.87% (current) yield; may keep these for a while | bountyhunter | |
16/6/2015 14:13 | The bid rumour is back - it's almost word per word the same as last time, does not mean it will not happen, however it certainly helps someone to offload a large line of stock, perhaps being a tad cynical. | essentialinvestor | |
16/6/2015 08:12 | Will bounce off support level soon ..... ;0) | tradermichael | |
16/6/2015 07:45 | "Pharmaceuticals giant GlaxoSmithKline could reportedly become the latest takeover target in the industry. According to the Daily Mail, market participants are speculating that the company may face an approach from Switzerland’s Roche or US company Johnson & Johnson at about 1900p per share. Such a move would value GSK at more than £92bn. Speaking over the weekend to Sharecast, Alistair McCaig, senior market analyst at IG, highlighted UK-listed pharmaceuticals as one of his favourites given the continuing need for American outfits to beef-up their product pipelines after a dearth of investment in recent years." Huge pinch of salt required - the Daily Mail was quoting "market sources" last year for bids on Morrisons, Unilever and Sainsburys. Having said that, I see GSk as a great company and it is definitely at a discount to peers. Why wouldn't there be interest at these levels? | unastubbs | |
15/6/2015 20:06 | GSK is a bond substitute and these should under-perform in a rising interest rate environment. Many blue chips, more so in the US than here, but GSK amongst that number, have optimised their balance sheet with cheap debt used to buy back shares. This is now neither attractive, because interest rates are rising, nor prudent because the balance sheet is so plump with debt. It shouldn't need saying but share buybacks actually occur at non-value price points because sellers are patient and momentum buyers are attracted, and holders don't sell as their equity share increases and the share is safer because it has a know buyer. The cessation or reduction of buybacks is an extremely dangerous time for a share price. This is far too soon to be buying and the fall is much quicker than I anticipated so alas I am not short. I'm really unsure what level may be optimum to buy given the speed of the descent. Eagle eyes on the chart really. | hpcg | |
15/6/2015 17:10 | Yes share price goes xd in early August I'm still waiting for my 1000 shares at 1300. Markets very weak atm. The trouble is there are several blue chips in so called bargain territory. | supermarky |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions